NCT04623541
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome treatment 1 / 2 recruiting NCT01171378
Study of Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone (CHOP) With Ofatumumab in Patients With Richter's Syndrome treatment 2 completed NCT02362035
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies treatment 1 / 2 active_not_recruiting NCT04939363
A Study to Evaluate the Efficacy and Safety of Obinutuzumab, Ibrutinib, and Venetoclax in Patients With Richter's Syndrome; treatment 2 recruiting NCT05665530
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies treatment 1 recruiting NCT02029443
ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia treatment 1 / 2 active_not_recruiting NCT03263637
Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies treatment 1 completed NCT03113695
Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome treatment 1 completed NCT02846623
Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome treatment 2 recruiting NCT04781855
Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation treatment 1 active_not_recruiting NCT05025800
ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma treatment 1 / 2 recruiting NCT05388006
Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation from Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma treatment 2 recruiting NCT03321643
Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma treatment 1 active_not_recruiting NCT02576990
Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170) treatment 2 completed NCT05923502
(CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL) Not Available Not Available not_yet_recruiting NCT03884998
Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma treatment 1 active_not_recruiting NCT01254578
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers treatment 1 completed NCT03899337
A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome treatment 2 recruiting NCT06521996
M-CHOP in Richter´s Syndrome treatment 2 recruiting NCT03054896
A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome treatment 2 recruiting NCT02535286
Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation treatment 1 completed NCT05672173
Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation treatment 2 recruiting NCT05176691
HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL No drug interventions treatment 1 withdrawn NCT03145480
Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients treatment 2 terminated NCT02285244
Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation treatment 2 withdrawn NCT03892044
Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma treatment 1 completed NCT03205046
A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies treatment 1 / 2 terminated NCT04679012
Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation treatment 2 recruiting NCT03534323
Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS treatment 1 / 2 active_not_recruiting NCT04978779
A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome treatment 1 terminated NCT01629511
Allogeneic Stem Cell Transplant for CLL treatment 1 / 2 terminated NCT02530515
Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia No drug interventions treatment 2 completed NCT04491370
Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma treatment 1 / 2 recruiting NCT03931642
BLINAtumomab After R-CHOP Debulking Therapy for Patients With Richter Transformation treatment 2 completed NCT03010358
Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma treatment 1 / 2 completed NCT06186648
Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome treatment 2 recruiting NCT02332980
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas treatment 2 completed NCT06247540
Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma treatment 2 withdrawn NCT03479268
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma treatment 1 active_not_recruiting NCT03619512
Genomic and Proteomic Study of Richter Syndrome (CGPSR) No drug interventions Not Available Not Available recruiting NCT02420912
Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation treatment 2 completed NCT05294731
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader No drug interventions treatment 1 / 2 recruiting NCT03162536
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) treatment 1 / 2 active_not_recruiting NCT03121534
Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation treatment 2 terminated NCT04806035
Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia treatment 1 terminated NCT03778073
Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma treatment 1 terminated NCT04305444
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas treatment 2 active_not_recruiting NCT02378038
PNT2258 for Treatment of Patients With Richter's Transformation (Brighton) treatment 2 terminated NCT01217749
Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL treatment 1 / 2 completed NCT00472849
Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias treatment 1 / 2 completed NCT02138786
Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation treatment 2 terminated NCT06043674
A Ph 2 Study of Glofitamab Alone or in Combination With Polatuzumab Vedotin or Atezolizumab in Richter's Transformation treatment 2 recruiting NCT02863692
Registry of the German CLL Study Group No drug interventions Not Available Not Available recruiting NCT03153514
Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter's Transformation Requiring Allogeneic Stem Cell Transplantation treatment 2 terminated NCT05828589
A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies No drug interventions treatment 1 recruiting NCT04271956
Efficacy and Safety of Zanubrutinib Plus Tislelizumab Treatment With or Without Sonrotoclax for Patients With Richter Transformation treatment 2 recruiting NCT05107674
A Study of NX-1607 in Adults With Advanced Malignancies treatment 1 recruiting NCT04771572
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. No drug interventions treatment 1 recruiting NCT04992377
R-EPOCH in Combination With Ibrutinib for Patients With Classical RT of CLL treatment 2 not_yet_recruiting